NO20003179L - Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat - Google Patents

Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat

Info

Publication number
NO20003179L
NO20003179L NO20003179A NO20003179A NO20003179L NO 20003179 L NO20003179 L NO 20003179L NO 20003179 A NO20003179 A NO 20003179A NO 20003179 A NO20003179 A NO 20003179A NO 20003179 L NO20003179 L NO 20003179L
Authority
NO
Norway
Prior art keywords
optionally substituted
pharmaceutical composition
ring
anilide derivative
antagonizing ccr5
Prior art date
Application number
NO20003179A
Other languages
English (en)
Other versions
NO20003179D0 (no
Inventor
Osamu Nishimura
Masanori Baba
Hidekazu Sawada
Naoyuki Kanzaki
Ken-Ichi Kuroshima
Mitsuru Shiraishi
Yoshio Aramaki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20003179L publication Critical patent/NO20003179L/no
Publication of NO20003179D0 publication Critical patent/NO20003179D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen tilveiebringer en farmasøytisk sammensetning for å antagonisere CCR5 som innbefatter en forbindelse med formel (1) hvori R1 er en valgfritt substituert 5- til 6-leddet ring; W er en divalent gruppe med formel (a) eller (b) hvori ringen A er en valgfritt substituert 5- til 6-leddet aromatisk ring, X er et valgfritt substituert C, N eller O-atom og ringen B er en valgfritt substituert 5- til 7-leddet ring; Z er en kjemisk binding eller en divalent gruppe; R2 er en valgfritt substituert aminogruppe hvori et nitrogenatom kan danne et kvarternært ammonium, etc., eller et salt derav.
NO20003179A 1997-12-19 2000-06-19 Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat NO20003179D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP35148097 1997-12-19
JP21887598 1998-08-03
JP23438898 1998-08-20
PCT/JP1998/005708 WO1999032100A2 (en) 1997-12-19 1998-12-17 Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative

Publications (2)

Publication Number Publication Date
NO20003179L true NO20003179L (no) 2000-06-19
NO20003179D0 NO20003179D0 (no) 2000-06-19

Family

ID=27330200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003179A NO20003179D0 (no) 1997-12-19 2000-06-19 Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat

Country Status (12)

Country Link
US (2) US6172061B1 (no)
EP (1) EP1039899A2 (no)
JP (1) JP2000128782A (no)
KR (1) KR20010032841A (no)
CN (1) CN1282243A (no)
AU (1) AU748064B2 (no)
BR (1) BR9813691A (no)
CA (1) CA2304959A1 (no)
HU (1) HUP0100199A2 (no)
ID (1) ID29994A (no)
NO (1) NO20003179D0 (no)
WO (1) WO1999032100A2 (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
FR2746101B1 (fr) * 1996-03-14 1998-04-30 Composes bicycliques-aromatiques
JP2002521441A (ja) * 1998-07-28 2002-07-16 スミスクライン・ビーチャム・コーポレイション Ｃｃｒ５モジュレーターとしてのプロペンアミド
WO2000010965A2 (en) * 1998-08-20 2000-03-02 Takeda Chemical Industries, Ltd. Quaternary ammonium salts and their use as anti-hiv agents
WO2000021916A1 (fr) * 1998-10-15 2000-04-20 Takeda Chemical Industries, Ltd. Procede de preparation de derives d'amine
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
WO2000037455A1 (en) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
WO2000068203A1 (en) * 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
WO2000069845A1 (en) 1999-05-18 2000-11-23 Takeda Chemical Industries, Ltd. Processes for the preparation of 2,3-dihydrothiepine derivatives
US6936602B1 (en) * 1999-06-16 2005-08-30 Takeda Chemical Industries, Ltd. Benzazepine derivatives, process for the preparation of the same and uses thereof
EP1211239A4 (en) * 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd PROCESSES FOR THE PREPARATION OF 2,3-DIHYDROAZEPINE COMPOUNDS
AU6870500A (en) * 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine derivatives
CA2385381A1 (en) * 1999-09-23 2001-03-29 Kenneth Ian Welsh Susceptibility gene for inflammatory bowel disease
EP1236476A1 (en) * 1999-12-10 2002-09-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2001232347A1 (en) * 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Process for producing cyclic compound
GEP20043285B (en) 2000-03-30 2004-07-26 Bristol Myers Squibb Co Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
WO2002034760A2 (en) * 2000-10-23 2002-05-02 Smithkline Beecham Corporation Compounds and methods
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
DE60235632D1 (de) * 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
WO2003014110A1 (en) * 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Benzazepine derivative, process for producing the same, and use
CN100412062C (zh) 2001-09-12 2008-08-20 阿诺麦德股份有限公司 对映体纯的氨基取代稠合双环的合成
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
WO2003090748A1 (fr) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
ES2571779T3 (es) * 2002-12-13 2016-05-26 Ym Biosciences Australia Pty Inhibidores de cinasa a base de nicotinamida
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
WO2004069833A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 縮環ピリジン誘導体、その製造法および用途
JP4736043B2 (ja) * 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CN101333185A (zh) * 2003-03-14 2008-12-31 小野药品工业株式会社 含氮杂环衍生物以及包含所述化合物作为活性成分的药物
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
GB0403038D0 (en) * 2004-02-11 2004-03-17 Novartis Ag Organic compounds
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
NZ552173A (en) * 2004-06-25 2010-07-30 Janssen Pharmaceutica Nv Quaternary salt CCR2 antagonists
KR101231466B1 (ko) 2004-09-13 2013-02-07 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CN101432025B (zh) * 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
AR065369A1 (es) * 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
US8093428B2 (en) * 2007-10-26 2012-01-10 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
US8168829B2 (en) * 2007-10-26 2012-05-01 Janssen Pharmaceutica N.V. Synthesis of quaternary salt compounds
CN102796075B (zh) * 2008-01-11 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
CN101481323B (zh) * 2008-01-11 2013-11-20 中国人民解放军军事医学科学院毒物药物研究所 苯并环庚烯类衍生物、其制备方法及医药用途
ES2545275T3 (es) * 2008-11-06 2015-09-09 Ventirx Pharmaceuticals, Inc. Métodos de síntesis de derivados de benzazepinas
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2016019587A1 (en) * 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
JP6716568B2 (ja) 2014-12-23 2020-07-01 トビラ セラピューティクス， インコーポレイテッド セニクリビロックの製造方法及び関連類似体
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CA3028151A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
RU2019109019A (ru) 2016-08-31 2020-10-01 Тобира Терапьютикс, Инк. Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата
ES2906992T3 (es) * 2016-12-09 2022-04-21 Medshine Discovery Inc Compuesto de bifenilo como antagonista del receptor CCR2/CCR5
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2021165960A1 (en) 2020-02-19 2021-08-26 Ichilov Tech Ltd. Improved antidepressant therapy
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN113735904B (zh) * 2021-09-17 2023-10-24 南京自一界科技研发有限公司 一种润滑添加剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69520360T2 (de) * 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
ZA9811576B (en) * 1997-12-19 2000-06-19 Takeda Chemical Industries Ltd Anilide derivative, production and use thereof.

Also Published As

Publication number Publication date
JP2000128782A (ja) 2000-05-09
CN1282243A (zh) 2001-01-31
EP1039899A2 (en) 2000-10-04
AU748064B2 (en) 2002-05-30
HUP0100199A2 (hu) 2001-04-28
US6172061B1 (en) 2001-01-09
BR9813691A (pt) 2000-10-10
WO1999032100A3 (en) 1999-09-10
ID29994A (id) 2001-10-25
AU1683199A (en) 1999-07-12
CA2304959A1 (en) 1999-07-01
WO1999032100A2 (en) 1999-07-01
KR20010032841A (ko) 2001-04-25
US6268354B1 (en) 2001-07-31
NO20003179D0 (no) 2000-06-19

Similar Documents

Publication Publication Date Title
NO20003179L (no) Farmasøytisk sammensetning for Õ antagonisere CCR5 som innbefatter anilid-derivat
NO20003133L (no) Anilid-derivat, fremstilling og anvendelse derav
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
BR0207809A (pt) Compostos heteroarila contendo nitrogênio possuindo atividade inibidora contra integrase de hiv
NO307047B1 (no) Nye hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere, farmasøytisk preparat inneholdende slike, og anvendelse derav
NO932620L (no) Amindiol-proteaseinhibitorer
NO970512L (no) Nye heteroaryl-oksazolidinoner
EP0528858A4 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
MXPA02012314A (es) Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
RU94044677A (ru) Трехзамещенные фенильные производные, способ получения, фармацевтическая композиция
AP9701041A0 (en) Pyridylpyrrole compounds.
DK0650961T3 (da) Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
TR199800924T2 (xx) Quinoline t�revleri.
CA2119647A1 (en) Heteroaryl Amines as Novel Acetylcholinesterase Inhibitors
CA2093077A1 (en) 2- and 3-amino and azido derivatives of 1,5-iminosugars
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
NO934718L (no) Nye HIV protease inhibitorer
CA2093076A1 (en) 2- and 3-amino and azido derivatives of 1,5-iminosugars
NO952205L (no) Heterocykliske karbamater, fremgangsmåte for fremstilling derav og medikamenter
DK492288D0 (da) Amidforbindelser, farmaceutisk praeparat indeholdende samme samt fremgangsmaade til fremstilling af forbindelserne
YU69699A (sh) Derivati aril karbonske kiseline i tetrazola
MX9707461A (es) Heterociclos nitrogenados de ciclohexilamino y ciclohexilalcoxi, metodos para preparar los mismos y su uso como agentes de control de pestes y fungicidas.
ATE175205T1 (de) Neue urethan enthaltende aminosteroid verbindungen
NO984921L (no) Tienopyridinderivater og deres anvendelser
CA2334012A1 (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application